v3.26.1
REVENUE RECOGNITION (Tables)
6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
SCHEDULE OF DISAGGREGATED BY PRODUCT

Revenue disaggregated by product for the three and six months ended June 30, 2026 and 2025 is as follows:

 

Product  2026   2025   2026   2025 
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
Product  2026   2025   2026   2025 
ARBLI™ (SCN-102, Losartan Potassium Oral Suspension)  $343,639   $-   $399,964   $- 
Pharmaceutical product resale   -    -    -    10,258 
Total revenues  $343,639   $-   $399,964   $10,258